First AF episode detected by the implantable loop recorder in patients that had a cryptogenic stroke. An AF episode will be considered an AF episode that lasts at least 2 minutes. [ Time Frame: Patients will be followed up during two years, regardless of reaching or not the primary endpoint. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

All subsequent AF episodes detected by the ILR after primary outcome (AF burden) [ Time Frame: Patients will be followed up during two years ] [ Designated as safety issue: No ]

AF episodes detected by external monitoring [ Time Frame: Patients will be followed up during two years ] [ Designated as safety issue: No ]

Presence of stroke, recurrent TIA, or silent infarction in neuroimaging [ Time Frame: Patients will be followed up during two years ] [ Designated as safety issue: No ]

Changes in anticoagulant therapy [ Time Frame: Patients will be followed up during two years ] [ Designated as safety issue: No ]

Observational study in patients with cryptogenic stroke (TOAST criteria) and with an implanted EKG loop recorder, with the primary objective of knowing the atrial fibrillation incidence in this population

Eligibility

Ages Eligible for Study:

45 Years to 85 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

Patients with cryptogenic stroke (TOAST criteria) and with an implantable EKG loop recorder implanted for detection of atrial fibrillation

Criteria

Inclusion Criteria:

All patients included must meet one of these two conditions:

Patient presenting with an episode of transient ischemic attack (TIA) of cryptogenic origin with neurological symptoms of less than 24h of evolution and negative neuroimaging.

First episode of ischaemic stroke with cryptogenic etiology following TOAST criteria

All patients must meet all of the following:

The patient has been implanted an ILR within 30 days after qualifying event

Age between 45-85 years

No stenosis >50% in any arterial vessel corresponding to the affected territory

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01025947